Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas.
BACKGROUND
Plasmablastic lymphoma (PBL) and multiple myeloma (MM) are B cell-derived malignancies that share many morphologic and immunophenotypic traits, making the differential diagnosis particularly complicated. We have recently demonstrated that peroxiredoxin I (PrdxI) is expressed in plasma cells but not in B lymphocytes, suggesting that its expression is development-associated.


OBJECTIVE
To analyze PrdxI expression in PBL and in MM in order to study its utilization as an additional diagnostic molecular tool.


RESULTS
Eight cases of PBL and nine of MM were studied by immunohistochemistry. We have demonstrated that PrdxI expression is closely connected with the immunoglobulin production capacity of the cells, which means high in MM, but absent in PBL cases, except one, wherein few cells were stained.


CONCLUSIONS
We hypothesize PrdxI as a component of the unfolded protein response (UPR), an adaptive pathway essential for plasma cell differentiation. As we have not detected immunoglobulin in our PBL cases, we suggest that UPR was not activated in the cells, accounting for the impediment of the developmental process, and for the inhibition of PrdxI expression observed. PrdxI could be considered an additional plasma cell functional marker and could also be speculated as a therapeutic target in the treatment of MM.
Demasi
A P D
AP
Department of Oral Pathology, São Leopoldo Mandic Dental Research Center, Campinas, Brazil. demasiap@lge.ibi.unicamp.br
Magalhães
M H C
MH
Furuse
C
C
Araújo
N S
NS
Junqueira
J L C
JL
Araújo
V C
VC
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D001402:B-Lymphocytes / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis; D002648:Child; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D007150:Immunohistochemistry; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics*; D054464:Peroxiredoxins / Q000032:analysis* / Q000235:genetics; D010950:Plasma Cells / Q000473:pathology; D010954:Plasmacytoma / Q000276:immunology
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D014408:Biomarkers, Tumor; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; C100347:VS38 monoclonal antibody; C515940:PRDX1 protein, human; D054464:Peroxiredoxins